日本behaperet病的流行病学和临床见解:2019年全国分析

IF 1.9 4区 医学 Q3 RHEUMATOLOGY
Yuki Mizuki, Nobuyuki Horita, Mitsuhiro Takeno, Akira Meguro, Yohei Kirino, Tatsukata Kawagoe, Takuto Sakono, Mami Ishihara, Shigeaki Ohno, Nobuhisa Mizuki
{"title":"日本behaperet病的流行病学和临床见解:2019年全国分析","authors":"Yuki Mizuki, Nobuyuki Horita, Mitsuhiro Takeno, Akira Meguro, Yohei Kirino, Tatsukata Kawagoe, Takuto Sakono, Mami Ishihara, Shigeaki Ohno, Nobuhisa Mizuki","doi":"10.1093/mr/roaf103","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Behçet's disease (BD) is a systemic inflammatory disorder with regional variations in its clinical manifestations. Although its characteristics have evolved over time, comprehensive data on the current epidemiology, treatment trends, and impact on daily life in Japan remain limited.</p><p><strong>Method: </strong>This study analysed the 2019 data from the National Database of Designated Intractable Diseases of Japan, provided by the Japanese Ministry of Health, Labour and Welfare (MHLW). We focused on age distribution, symptom frequency, daily life impact, and treatment trends.</p><p><strong>Results: </strong>In the 2019 database, 10 406 patients with BD were registered. The median age was 55 years, with a higher proportion of women affected (53.2%). Serious manifestations such as ocular, vascular, and CNS involvement were more frequent in males, whereas females showed more mucocutaneous and articular symptoms, representing mild forms of the disease. Pharmacological treatment was common (93.8%), with corticosteroids (44.3%), colchicine (50.9%), infliximab (17.0%), and adalimumab (9.6%) being frequently used. BD significantly affected daily life, with nearly one-third experiencing impaired mobility or depression.</p><p><strong>Conclusion: </strong>This nationwide analysis highlighted sex-based differences in clinical features and found that BD continues to substantially affect quality of life. The widespread use of biologics suggests a shift in therapeutic strategies.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Epidemiological and Clinical Insights into Behçet's Disease in Japan: A 2019 Nationwide Analysis.\",\"authors\":\"Yuki Mizuki, Nobuyuki Horita, Mitsuhiro Takeno, Akira Meguro, Yohei Kirino, Tatsukata Kawagoe, Takuto Sakono, Mami Ishihara, Shigeaki Ohno, Nobuhisa Mizuki\",\"doi\":\"10.1093/mr/roaf103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Behçet's disease (BD) is a systemic inflammatory disorder with regional variations in its clinical manifestations. Although its characteristics have evolved over time, comprehensive data on the current epidemiology, treatment trends, and impact on daily life in Japan remain limited.</p><p><strong>Method: </strong>This study analysed the 2019 data from the National Database of Designated Intractable Diseases of Japan, provided by the Japanese Ministry of Health, Labour and Welfare (MHLW). We focused on age distribution, symptom frequency, daily life impact, and treatment trends.</p><p><strong>Results: </strong>In the 2019 database, 10 406 patients with BD were registered. The median age was 55 years, with a higher proportion of women affected (53.2%). Serious manifestations such as ocular, vascular, and CNS involvement were more frequent in males, whereas females showed more mucocutaneous and articular symptoms, representing mild forms of the disease. Pharmacological treatment was common (93.8%), with corticosteroids (44.3%), colchicine (50.9%), infliximab (17.0%), and adalimumab (9.6%) being frequently used. BD significantly affected daily life, with nearly one-third experiencing impaired mobility or depression.</p><p><strong>Conclusion: </strong>This nationwide analysis highlighted sex-based differences in clinical features and found that BD continues to substantially affect quality of life. The widespread use of biologics suggests a shift in therapeutic strategies.</p>\",\"PeriodicalId\":18705,\"journal\":{\"name\":\"Modern Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mr/roaf103\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf103","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:behet病(BD)是一种全身性炎症性疾病,其临床表现具有区域性差异。尽管其特征随着时间的推移而发生变化,但有关日本当前流行病学、治疗趋势及其对日常生活影响的综合数据仍然有限。方法:本研究分析了日本厚生劳动省(MHLW)提供的2019年日本国家指定顽固性疾病数据库的数据。我们关注年龄分布、症状频率、日常生活影响和治疗趋势。结果:在2019年的数据库中,登记了10 406例BD患者。中位年龄为55岁,女性患者比例较高(53.2%)。严重的表现,如眼部、血管和中枢神经系统受累,在男性中更为常见,而女性则表现出更多的粘膜皮肤和关节症状,代表了疾病的轻度形式。药物治疗是常见的(93.8%),其中皮质类固醇(44.3%)、秋水仙碱(50.9%)、英夫利昔单抗(17.0%)和阿达木单抗(9.6%)是常用的治疗方法。双相障碍严重影响了日常生活,近三分之一的人经历了行动障碍或抑郁。结论:这项全国性的分析强调了临床特征的性别差异,并发现双相障碍继续显著影响生活质量。生物制剂的广泛使用表明了治疗策略的转变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Epidemiological and Clinical Insights into Behçet's Disease in Japan: A 2019 Nationwide Analysis.

Background: Behçet's disease (BD) is a systemic inflammatory disorder with regional variations in its clinical manifestations. Although its characteristics have evolved over time, comprehensive data on the current epidemiology, treatment trends, and impact on daily life in Japan remain limited.

Method: This study analysed the 2019 data from the National Database of Designated Intractable Diseases of Japan, provided by the Japanese Ministry of Health, Labour and Welfare (MHLW). We focused on age distribution, symptom frequency, daily life impact, and treatment trends.

Results: In the 2019 database, 10 406 patients with BD were registered. The median age was 55 years, with a higher proportion of women affected (53.2%). Serious manifestations such as ocular, vascular, and CNS involvement were more frequent in males, whereas females showed more mucocutaneous and articular symptoms, representing mild forms of the disease. Pharmacological treatment was common (93.8%), with corticosteroids (44.3%), colchicine (50.9%), infliximab (17.0%), and adalimumab (9.6%) being frequently used. BD significantly affected daily life, with nearly one-third experiencing impaired mobility or depression.

Conclusion: This nationwide analysis highlighted sex-based differences in clinical features and found that BD continues to substantially affect quality of life. The widespread use of biologics suggests a shift in therapeutic strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Modern Rheumatology
Modern Rheumatology RHEUMATOLOGY-
CiteScore
4.90
自引率
9.10%
发文量
146
审稿时长
1.5 months
期刊介绍: Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信